NATIONAL-TSING
12.5.2020 11:02:12 CEST | Business Wire | Press release
On May 9 National Tsing Hua University entered into an agreement to jointly establish the Taipei School of Economics and Political Science (TSE) together with the TSE Foundation, which was set up with a US$100 million donation from entrepreneur Lin Chen-hai, the founder of the Pau Jar Group. The mission of the TSE will be to provide world-class education in economics, international politics, and public affairs, with Asia as the center of gravity, and will soon begin recruiting top-notch faculty from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005343/en/
At the signing ceremony, TSE Foundation chairman Huang Huang-hsiung said that the TSE will be located on the NTHU campus, and that this type of cooperation between the public and private sectors is a new first in the history of higher education in Taiwan.
Also present at the ceremony was Minister of Education Pan Wen-chung, who said that the establishment of the TSE is undoubtedly a new milestone for higher education in Taiwan. NTHU president Hocheng Hong said that the plan for establishing the TSE has already been approved by the Ministry of Education, and that it will soon begin recruiting master’s and doctoral students for the 2021-22 school year, two thirds of whom will be international students, adding that all courses will be taught in English.
Chairman Huang said that the TSE aims to attract outstanding students and world-class faculty, for which purpose he is helping to set up an international advisory committee, which includes four former ministers of education to arrange academic exchanges with such well-known institutions as the London School of Economics(LSE) and the Harvard Kennedy School.
NTHU president Hocheng Hong said that public-private cooperation in education on such a scale is unprecedented, pointing out that Lin’s US$100 million donation is the largest ever made in the field of social science education in Taiwan.
Hocheng asserted that technology is a major factor in all of the most pressing challenges facing humanity, such as food security, environmental preservation, energy, war, and even epidemics, and that any viable solution must take account of technological, political, and economic factors, adding that this was one of the principle motivations for establishing the TSE at National Tsing Hua University.
Hocheng said that the TSE will be the eleventh college at NTHU, and that its multi-disciplinary master’s and doctoral programs will be modeled on those of the LSE. The TSE plans to admit at least ten master’s students for the 2021-22 school year, and in the following school year at least 40 master’s students and ten doctoral students, after which enrollment numbers will gradually increase year by year. During the initial phase, TSE classes will be held in the Innovation Incubation Building on the NTHU campus, until the program’s own building is completed both on campus and in Taipei.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005343/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
